RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IRLAB Therapeutics - Stock

IRLAB Therapeutics Employees 2024

IRLAB Therapeutics Employees

22

Ticker

IRLAB A.ST

ISIN

SE0012675361

WKN

A2PLBE

In 2024, IRLAB Therapeutics employed 22 people, a 0% change from the 22 number of employees in the previous year.

IRLAB Therapeutics Aktienanalyse

What does IRLAB Therapeutics do?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining IRLAB Therapeutics's Employee Base

IRLAB Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding IRLAB Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing IRLAB Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

IRLAB Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in IRLAB Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about IRLAB Therapeutics stock

How many employees does IRLAB Therapeutics have this year?

IRLAB Therapeutics has 22 undefined employees this year.

How many employees did IRLAB Therapeutics have compared to the previous year?

Compared to the previous year, IRLAB Therapeutics had 0% more employees.

What impact did the number of employees have on the company IRLAB Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of IRLAB Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of IRLAB Therapeutics?

The number of employees can also have an impact on investors of IRLAB Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of IRLAB Therapeutics affect the company?

An increase in equity of IRLAB Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in IRLAB Therapeutics's equity affect the company?

A reduction in equity of IRLAB Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of IRLAB Therapeutics?

Some factors that can influence the equity of IRLAB Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of IRLAB Therapeutics so important for investors?

The equity of IRLAB Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at IRLAB Therapeutics influence the company?

The number of employees at IRLAB Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at IRLAB Therapeutics evolved in recent years?

In recent years, the number of employees at IRLAB Therapeutics has changed by 0.

How many employees does IRLAB Therapeutics currently have?

IRLAB Therapeutics currently has 22 undefined employees.

Why is the number of employees important for investors of IRLAB Therapeutics?

The number of employees is important for investors of IRLAB Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can IRLAB Therapeutics take to change the number of employees?

To change the number of employees, IRLAB Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does IRLAB Therapeutics pay?

Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of IRLAB Therapeutics?

The current dividend yield of IRLAB Therapeutics is .

When does IRLAB Therapeutics pay dividends?

IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRLAB Therapeutics?

IRLAB Therapeutics paid dividends every year for the past 0 years.

What is the dividend of IRLAB Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRLAB Therapeutics located?

IRLAB Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRLAB Therapeutics from 7/8/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did IRLAB Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of IRLAB Therapeutics in the year 2023?

In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.

In which currency does IRLAB Therapeutics pay out the dividend?

The dividends of IRLAB Therapeutics are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IRLAB Therapeutics

Our stock analysis for IRLAB Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRLAB Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.